DARTS Technology Launches New Drug Target Identification Service Designed To Streamline Drug Development

Enables Identification of Potential Side Effects Before Trials

NEW YORK--(BUSINESS WIRE)--DARTS Sciences, Inc. (www.dartssciences.com) has obtained an exclusive license for the DARTS patent (Drug Affinity Responsive Target Stability Technology), and is the sole provider of the cutting edge technology designed to streamline drug development and save pharmaceutical and biotech companies significant time and money by identify a drug’s target of actions, it was announced today by Dr. Jack Kavanaugh, CEO and Chairman of the company. Dr. Kavanaugh was also the founder and CEO of ZetaRX which became the core component of Juno Therapeutics. Said Kavanaugh, “I believe that DARTS will revolutionize molecular screening for therapeutic effectiveness, avoidance of side-effects and development of beneficial applications thereby benefitting patients.”

“I believe that DARTS will revolutionize molecular screening for therapeutic effectiveness, avoidance of side-effects and development of beneficial applications thereby benefitting patients.”

DARTS Sciences was founded by UCLA professor Dr. Jing Huang, who invented the technology, Dr. Brett Lomenick, also of UCLA and COO of the company, and Dr. Kavanaugh.

With DARTS Sciences paradigm-changing technology, pharmaceutical and biotech companies will be able to identify therapeutic targets, predict side-effects early in their drug development efforts and identify repurposing targets of existing drugs. This will accelerate pre-clinical and clinical drug discovery drug development and diagnostic development.

The ground breaking technology allows (1) unbiased proteome-wide drug target identification using state-of-the-art proteomics and mass spectrometry technologies, (2) specific analysis of candidate drug targets, and (3) drug screening against any protein target of interest. DARTS technology uses the native, unmodified drugs, complex protein lysates from any cell or tissue type or subcellular fraction and relies solely on the binding interaction between the drug and its target proteins. Furthermore, DARTS is applicable to any class of compounds regardless of structure, mechanism of action or therapeutic area and is already providing services to customers.